FDA Turns To Epidemiological Data To Resolve Azilect Melanoma Questions
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA used an epidemiological approach to resolve concerns regarding a potentially higher risk of melanoma with Teva’s Parkinson’s disease therapy Azilect, review documents show.
You may also be interested in...
Teva Opts For Azilect Tyramine Warning Rather Than Conduct "Adequate" Study
Teva agreed to a tyramine sensitivity warning in labeling for Azilect (rasagiline) after FDA deemed the firm's studies inadequate to characterize the problem
Teva Agilect "approvable" again
Teva Parkinson's disease treatment Agilect (rasagiline) receives a second "approvable" letter Aug. 4. "There remain a number of issues that Teva believed it had resolved with its submissions, but [where] FDA continues to have concerns," the sponsor states Aug. 5. The firm plans to meet with the agency "promptly" to address the remaining concerns. Teva responded to a July 2004 approvable letter last November, but the review was extended by three months due to a technical error with the NDA...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011